{"filing":{"accession_number":"0001104659-26-093371","cik":"0001561921","ticker":"TELA","company_name":"TELA Bio, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"tm2622768d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/tm2622768d1_8k.htm"},"events":[{"id":26583,"run_id":24164,"accession_number":"0001104659-26-093371","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"TELA Bio issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended June 30, 2026, with consolidated statements of operations and balance sheets attached as Exhibit 99.1. The disclosure includes revenue of $19.3 million (down 4% YoY), net loss of $11.3 million, and cash position of $30.4 million, along with withdrawal of full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and cash runway.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27753,"accession_number":"0001104659-26-093371","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TELA Bio issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended June 30, 2026, with consolidated statements of operations and balance sheets attached as Exhibit 99.1. The disclosure includes revenue of $19.3 million (down 4% YoY), net loss of $11.3 million, and cash position of $30.4 million, along with withdrawal of full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:20:03.839700+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27753,"accession_number":"0001104659-26-093371","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TELA Bio issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended June 30, 2026, with consolidated statements of operations and balance sheets attached as Exhibit 99.1. The disclosure includes revenue of $19.3 million (down 4% YoY), net loss of $11.3 million, and cash position of $30.4 million, along with withdrawal of full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:20:03.839700+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-10"}]}